Literature DB >> 31169324

Susceptibility to adverse drug reactions.

Robin Ferner1,2, Jeffrey Aronson1,3.   

Abstract

The pharmacological effects of a drug depend on its concentration at the site of action, and therefore on the concentration in blood and on the dose. The relationship between the concentration or dose and the corresponding effect can usually be represented mathematically as a rectangular hyperbola; when effect is plotted against log concentration or log dose, the curve is sigmoidal. Inevitably, the effect size and the doses causing benefit and harm will differ among individuals, since they are biological phenomena: some individuals are more likely than others to suffer harm at any given dose. Some harmful effects can occur at much lower doses than those used in therapeutics; that is, the log dose-response curve for harm lies far to the left of the log dose-response curve for benefit. Those who suffer such reactions are hypersusceptible. When the dose-response curves for harm and therapeutic effect are in the same range, dose cannot separate the harmful effects from the therapeutic effects, and adverse reactions are collateral. Toxic effects occur when harmful doses are above the doses needed for benefit. In this review we consider factors that influence a subject's susceptibility to adverse drug reactions. Determinants of susceptibility include Immunological, Genetic, demographic (Age and Sex), Physiological and Exogenous factors (drug-drug interactions, for example), and Diseases and disorders such as renal failure, giving the mnemonic I GASPED. Some susceptibility factors are discrete (for example, all-or-none) and some are continuous; susceptibility can therefore be discrete or continuous; and the factors can interact to determine a person's overall susceptibility to harm.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  adverse drug reactions; genetic polymorphisms; pharmacodynamics; pharmacokinetics; prescribing

Year:  2019        PMID: 31169324      PMCID: PMC6783620          DOI: 10.1111/bcp.14015

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  62 in total

1.  A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.

Authors:  Agnès Sommet; Genevieve Durrieu; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-12-08       Impact factor: 2.890

Review 2.  Joining the DoTS: new approach to classifying adverse drug reactions.

Authors:  J K Aronson; R E Ferner
Journal:  BMJ       Date:  2003-11-22

3.  The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker.

Authors:  E BEUTLER; M YEH; V F FAIRBANKS
Journal:  Proc Natl Acad Sci U S A       Date:  1962-01-15       Impact factor: 11.205

4.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

5.  Atropinesterase, a Genetically Determined Enzyme in the Rabbit.

Authors:  P B Sawin; D Glick
Journal:  Proc Natl Acad Sci U S A       Date:  1943-02       Impact factor: 11.205

6.  Interactions with the absorption of tetracyclines.

Authors:  P J Neuvonen
Journal:  Drugs       Date:  1976       Impact factor: 9.546

7.  Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis.

Authors:  C Goulenok; B Bernard; J F Cadranel; D Thabut; V Di Martino; P Opolon; T Poynard
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

Review 8.  Immediate-type hypersensitivity drug reactions.

Authors:  Shelley F Stone; Elizabeth J Phillips; Michael D Wiese; Robert J Heddle; Simon G A Brown
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

9.  Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies.

Authors:  R M Martin; P N Biswas; S N Freemantle; G L Pearce; R D Mann
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

10.  Extrapyramidal reactions with metoclopramide.

Authors:  D N Bateman; M D Rawlins; J M Simpson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-05
View more
  11 in total

Review 1.  Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.

Authors:  Simon B Dimmitt; Hans G Stampfer; Jennifer H Martin; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

Review 2.  Why maximum tolerated dose?

Authors:  Hans G Stampfer; Genevieve M Gabb; Simon B Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

3.  Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review.

Authors:  Elisabetta Chessa; Matteo Piga; Alberto Floris; Mattia Congia; Ignazio Cangemi; Alessandro Mathieu; Alberto Cauli
Journal:  BioDrugs       Date:  2021-02-17       Impact factor: 5.807

4.  Statin doses after acute coronary syndrome.

Authors: 
Journal:  Aust Prescr       Date:  2022-04-01

5.  Risk factors for adverse drug reactions associated with clopidogrel therapy.

Authors:  Snezana Mugosa; Ivan Radosavljevic; Majda Sahman; Natasa Djordjevic; Zoran Todorovic
Journal:  Open Med (Wars)       Date:  2022-04-07

Review 6.  Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.

Authors:  Annette S Gross; Anya C Harry; Christine S Clifton; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2022-02-17       Impact factor: 3.716

7.  Artificial Intelligence, Real-World Automation and the Safety of Medicines.

Authors:  Andrew Bate; Steve F Hobbiger
Journal:  Drug Saf       Date:  2020-10-07       Impact factor: 5.606

Review 8.  On precision dosing of oral small molecule drugs in oncology.

Authors:  Alex K Lyashchenko; Serge Cremers
Journal:  Br J Clin Pharmacol       Date:  2020-07-17       Impact factor: 4.335

9.  Precision medicine technology hype or reality? The example of computer-guided dosing.

Authors:  Thomas M Polasek; Sepehr Shakib; Amin Rostami-Hodjegan
Journal:  F1000Res       Date:  2019-10-01

10.  Commentary on Health service use and costs associated with fluoroquinolone-related tendon injuries.

Authors:  Michael Kennedy
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.